Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma

February 4, 2013, from MedWorm: Brain Tumor

Conclusion: Everolimus therapy is safe and effective for longer term (median exposure 34.2 months) treatment of patients with TSC with SEGA. Classification of evidence: This study provides Class III evidence that everolimus, titrated to trough serum levels of 5–15 ng/mL, was effective in reducing tumor size in patients with SEGA secondary to TSC for a median of 34 months. (Source: Neurology)

MedWorm Sponsor Message: Have a look at The Cancer and Oncology Daily, the new cancer portal with all the latest cancer news and research powered by MedWorm, updated daily.

View Source